Novel and Improved Technologies for Tuberculosis Diagnosis: Progress and Challenges

Clinics in Chest Medicine

Volumn 30, Issue 4, 2009, Pages 701-716

  Pai, Madhukar ^a   Minion, Jessica ^a   Sohn, Hojoon ^a,b   Zwerling, Alice ^a   Perkins, Mark D ^b  

^a MCGILL UNIVERSITY   (Canada)

^b FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

Author keywords

Diagnostics; New tools; Sensitivity and specificity; Tuberculosis

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; BCG VACCINE; GAMMA INTERFERON; ISONIAZID; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBODY DETECTION; ANTIGEN DETECTION; AUTOMATION; BACTERIUM CULTURE; BACTERIUM DETECTION; CHILDHOOD DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CULTURE TECHNIQUE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; EXTRAPULMONARY TUBERCULOSIS; FALSE POSITIVE RESULT; HUMAN; IMMUNOASSAY; LABORATORY TEST; LUNG TUBERCULOSIS; MEDICAL TECHNOLOGY; MICROSCOPY; MOLECULAR BIOLOGY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; SPUTUM SMEAR; STANDARDIZATION; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; TUBERCULOUS PERICARDITIS; TUBERCULOUS PERITONITIS; TUBERCULOUS PLEURISY;

BACTERIOLOGICAL TECHNIQUES; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HUMANS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 71549114522     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2009.08.016     Document Type: Review

References (75)

1. Perkins M.D., and Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis 196 Suppl 1 (2007) S15-S27
2. Pai M., and O'Brien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med 29 (2008) 560-568
3. Sreeramareddy C.T., Kishore P.V., Menten J., et al. Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect Dis 9 (2009) 91
4. Perkins M.D., Roscigno G., and Zumla A. Progress towards improved tuberculosis diagnostics for developing countries. Lancet 367 (2006) 942-943
5. Perkins M.D., and Small P.M. Partnering for better microbial diagnostics. Nat Biotechnol 24 (2006) 919-921
6. Minion J., Zwerling A., and Pai M. Diagnostics for tuberculosis: what new knowledge did we gain through the International Journal of Tuberculosis and Lung Disease in 2008?. Int J Tuberc Lung Dis 13 (2009) 691-697
7. Stop TB Partnership, and World Health Organization. The global plan to stop TB 2006-2015 (2006), World Health Organization, Geneva (Switzerland)
8. Pai M., Ramsay A., and O'Brien R. Evidence-based tuberculosis diagnosis. PLoS Med 5 (2008) e156
9. World Health Organization. Moving research findings into new WHO policies (2008), World Health Organization, Geneva (Switzerland). http://www.who.int/tb/dots/laboratory/policy/en/index4.html Accessed October 1, 2009
10. World Health Organization, and Stop TB Partnership. New laboratory diagnostic tools for tuberculosis control (2008), World Health Organization, In: Geneva (Switzerland)
11. Steingart K.R., Henry M., Ng V., et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 6 (2006) 570-581
12. Steingart K.R., Ng V., Henry M., et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 6 (2006) 664-674
13. Steingart K.R., Ramsay A., and Pai M. Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis. Expert Rev Anti Infect Ther 5 (2007) 327-331
14. Mase S.R., Ramsay A., Ng V., et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 11 (2007) 485-495
15. Cambanis A., Yassin M.A., Ramsay A., et al. A one-day method for the diagnosis of pulmonary tuberculosis in rural Ethiopia. Int J Tuberc Lung Dis 10 (2006) 230-232
16. Minion J., Sohn H., and Pai M. Light-emitting diode technologies for TB diagnosis: what's on the market?. Expert Rev Med Devices 6 4 (2009) 341-345
17. Breslauer D.N., Maamari R.N., Switz N.A., et al. Mobile phone based clinical microscopy for global health applications. PLoS One 4 (2009) e6320
18. Sadaphal P., Rao J., Comstock G.W., et al. Image processing techniques for identifying Mycobacterium tuberculosis in Ziehl-Neelsen stains. Int J Tuberc Lung Dis 12 (2008) 579-582
19. Dinnes J., Deeks J., Kunst H., et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 11 (2007) 1-178
20. Cruciani M., Scarparo C., Malena M., et al. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol 42 (2004) 2321-2325
21. Ngamlert K., Sinthuwattanawibool C., McCarthy K.D., et al. Diagnostic performance and costs of Capilia TB for Mycobacterium tuberculosis complex identification from broth-based culture in Bangkok, Thailand. Trop Med Int Health 14 (2009) 748-753
22. World Health Organization. The use of liquid medium for culture and DST (2007), World Health Organization, Geneva (Switzerland). http://www.who.int/tb/dots/laboratory/policy/en/index3.html Accessed October 1, 2009
23. Moore D.A., Evans C.A., Gilman R.H., et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 355 (2006) 1539-1550
24. Martin A., Munga Waweru P., Babu Okatch F., et al. Implementation of the thin layer agar for the diagnosis of smear-negative pulmonary tuberculosis in a high HIV prevalence setting in Homa Bay, Kenya. J Clin Microbiol 47 (2009) 2632-2634
25. Shikama M.L., Ferro e Silva R., Villela G., et al. Multicentre study of nitrate reductase assay for rapid detection of rifampicin-resistant M. tuberculosis. Int J Tuberc Lung Dis 13 (2009) 377-380
26. Palomino J.C. Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field. Eur Respir J 26 (2005) 339-350
27. Bwanga F., Hoffner S., Haile M., et al. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis 9 (2009) 67
28. Palomino J.C. Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 56 (2009) 103-111
29. Centers for Disease Control and Prevention. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 58 (2009) 7-10
30. Greco S., Girardi E., Navarra S., et al. The current evidence on diagnostic accuracy of commercial based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis. Thorax 61 (2006) 783-790
31. Ling D.I., Flores L.L., Riley L.W., et al. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS One 3 (2008) e1536
32. Pai M., Flores L.L., Hubbard A., et al. Nucleic acid amplification tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis. BMC Infect Dis 4 (2004) 6
33. Pai M., Flores L.L., Pai N., et al. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 3 (2003) 633-643
34. Boehme C.C., Nabeta P., Henostroza G., et al. Operational feasibility of using loop-mediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries. J Clin Microbiol 45 (2007) 1936-1940
35. Cepheid announces new diagnostic technology in ongoing efforts to halt the spread of TB. Available at:. http://www.finddiagnostics.org/export/sites/default/media/press/090324.html Foundation for Innovative New Diagnostics, 2009. Accessed June 17, 2009
36. Morgan M., Kalantri S., Flores L., et al. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 5 (2005) 62
37. Ling D.I., Zwerling A.A., and Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 32 (2008) 1165-1174
38. Hillemann D., Rusch-Gerdes S., and Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 47 (2009) 1767-1772
39. Policy statement. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB) (2008), World Health Organization. http://www.who.int/tb/features_archive/policy_statement.pdf World Health Organization. Accessed October 1, 2009
40. UNITAID approves over US $61 million to GLI, FIND and GDF for MDR-TB diagnostics. Available at:. http://www.finddiagnostics.org/export/sites/default/media/news/090518.html Foundation for Innovative New Diagnostics, 2009. Accessed June 17, 2009
41. Steingart K.R., Henry M., Laal S., et al. A systematic review of commercial serological antibody detection tests for the diagnosis of extra-pulmonary tuberculosis. Thorax 62 (2007) 911-918
42. Steingart K.R., Henry M., Laal S., et al. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med 4 (2007) e202
43. World Health Organization. Diagnostics Evaluation Series No.2. Laboratory-based evaluation of 19 commercially available rapid diagnostic tests for tuberculosis (2008), World Health Organization, Geneva (Switzerland)
44. Steingart K.R., Dendukuri N., Henry M., et al. Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin Vaccine Immunol 16 (2009) 260-276
45. Boehme C., Molokova E., Minja F., et al. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg 99 (2005) 893-900
46. Daley P., Michael J.S., Hmar P., et al. Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study. Int J Tuberc Lung Dis 13 8 (2009) 989-995
47. Mutetwa R., Boehme C., Dimairo M., et al. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African TB suspects and patients. Int J Tuberc Lung Dis 13 10 (2009) 1253-1259
48. Lawn S.D., Edwards D., Kranzer K., et al. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 23 14 (2009) 1875-1880
49. Farhat M., Greenaway C., Pai M., et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. Int J Tuberc Lung Dis 10 (2006) 1192-1204
50. Menzies D., Pai M., and Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146 (2007) 340-354
51. Pai M., Zwerling A., and Menzies D. T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149 (2008) 177-184
52. Zwerling A., Behr M., Brewer T., et al. Which countries are most likely to benefit from highly specific IGRAs? Findings from the World Atlas of BCG Policies and Practices. Am J Respir Crit Care Med 179 (2009) A4773
53. Lange C., Pai M., Drobniewski F., et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: sensible or silly?. Eur Respir J 33 (2009) 1250-1253
54. Pai M., and Menzies D. Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis?. Clin Infect Dis 44 (2007) 74-77
55. Pai M. Guidelines on IGRAs: concordant or discordant? In: 2nd Global symposium on IGRAs; May 30-June 1, 2009; Dubrovnik, Croatia: 2009.
56. Pai M., Dheda K., Cunningham J., et al. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis 7 (2007) 428-438
57. Dheda K., Smit R.Z., Badri M., et al. T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Curr Opin Pulm Med 15 (2009) 188-200
58. Arend S.M., Franken W.P., Aggerbeck H., et al. Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis 88 (2008) 249-261
59. Wu X., Zhang L., Zhang J., et al. Recombinant early secreted antigen target 6 protein as a skin test antigen for the specific detection of Mycobacterium tuberculosis infection. Clin Exp Immunol 152 (2008) 81-87
60. Kiselev V.I., Baranovsky P.M., Rudykh I.V., et al. [Clinical trials of the new skin test Diaskintest for the diagnosis of tuberculosis]. Probl Tuberk Bolezn Legk 2 (2009) 11-16 [in Russian]
61. Paris Meeting on TB Point-of-Care Test Specifications. Available at:. http://www.msfaccess.org/TB_POC_Parismeeting/ Médecins Sans Frontières, 2009. Accessed June 17, 2009
62. X PRIZE Foundation to Help Fight Tuberculosis Worldwide with Gates Foundation Support. URL. http://www.xprize.org/foundation/press-release/x-prize-foundation-to-help-fight-tuberculosis-worldwide-with-gates-foundati XPrize Foundation, 2008. Accessed June 17, 2009
63. Marais B.J., Gie R.P., Schaaf H.S., et al. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med 173 (2006) 1078-1090
64. Marais B.J., and Pai M. New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr Respir Rev 8 (2007) 124-133
65. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Can Commun Dis Rep 34 (2008) 1-13
66. Mazurek G.H., Jereb J., Lobue P., et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54 (2005) 49-55
67. Hopewell P.C., Pai M., Maher D., et al. International standards for tuberculosis care. Lancet Infect Dis 6 (2006) 710-725
68. Sohn H., Minion J., Albert H., et al. TB diagnostic tests: how do we figure out their costs?. Expert Rev Anti Infect Ther 7 6 (2009) 723-733
69. Dowdy D.W., O'Brien M.A., and Bishai D. Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 12 (2008) 1021-1029
70. Keeler E., Perkins M.D., Small P., et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 444 Suppl 1 (2006) 49-57
71. Dowdy D.W., Chaisson R.E., Maartens G., et al. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A 105 (2008) 11293-11298
72. Dowdy D.W., Chaisson R.E., Moulton L.H., et al. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS 20 (2006) 751-762
73. Dowdy D.W., Lourenco M.C., Cavalcante S.C., et al. Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS One 3 (2008) e4057
74. Mueller D.H., Mwenge L., Muyoyeta M., et al. Costs and cost-effectiveness of tuberculosis cultures using solid and liquid media in a developing country. Int J Tuberc Lung Dis 12 (2008) 1196-1202
75. Acuna-Villaorduna C., Vassall A., Henostroza G., et al. Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis 47 (2008) 487-495